DE602006020568D1 - Stabile wässrige systeme mit proteinen - Google Patents

Stabile wässrige systeme mit proteinen

Info

Publication number
DE602006020568D1
DE602006020568D1 DE602006020568T DE602006020568T DE602006020568D1 DE 602006020568 D1 DE602006020568 D1 DE 602006020568D1 DE 602006020568 T DE602006020568 T DE 602006020568T DE 602006020568 T DE602006020568 T DE 602006020568T DE 602006020568 D1 DE602006020568 D1 DE 602006020568D1
Authority
DE
Germany
Prior art keywords
protein
ionisable groups
stabilising
proteins
aqueous systems
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006020568T
Other languages
English (en)
Inventor
Jan Jezek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arecor Ltd
Original Assignee
Arecor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36940697&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602006020568(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0513653.6A external-priority patent/GB0513653D0/en
Priority claimed from GBGB0610140.6A external-priority patent/GB0610140D0/en
Application filed by Arecor Ltd filed Critical Arecor Ltd
Publication of DE602006020568D1 publication Critical patent/DE602006020568D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE602006020568T 2005-07-02 2006-07-03 Stabile wässrige systeme mit proteinen Active DE602006020568D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0513653.6A GB0513653D0 (en) 2005-07-02 2005-07-02 Protein stability
GBGB0610140.6A GB0610140D0 (en) 2006-05-22 2006-05-22 Protein stability
PCT/GB2006/002470 WO2007003936A1 (en) 2005-07-02 2006-07-03 Stable aqueous systems comprising proteins

Publications (1)

Publication Number Publication Date
DE602006020568D1 true DE602006020568D1 (de) 2011-04-21

Family

ID=36940697

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006020568T Active DE602006020568D1 (de) 2005-07-02 2006-07-03 Stabile wässrige systeme mit proteinen

Country Status (8)

Country Link
US (1) US20090148406A1 (de)
EP (3) EP2264161A1 (de)
JP (1) JP5033798B2 (de)
AT (1) ATE501248T1 (de)
CA (1) CA2614006C (de)
DE (1) DE602006020568D1 (de)
DK (1) DK1899462T3 (de)
WO (1) WO2007003936A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0610140D0 (en) 2006-05-22 2006-06-28 Insense Ltd Protein stability
GB2435510A (en) * 2006-02-23 2007-08-29 Mologic Ltd Enzyme detection product and methods
US20090136538A1 (en) * 2006-05-22 2009-05-28 Jan Jezek Stable vaccine formulation
GB0626021D0 (en) 2006-12-29 2007-02-07 Insense Ltd The stabilisation of proteins
GB0700523D0 (en) * 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
CN101679507A (zh) 2007-03-29 2010-03-24 艾博特公司 结晶抗人类il-12抗体
JP5273438B2 (ja) * 2007-11-22 2013-08-28 国立大学法人東京農工大学 ペプチド付加生体分子の溶解度計算方法、及びそれを用いたペプチドタグの設計方法と封入体形成防止方法
SG10201604258YA (en) * 2007-11-30 2016-07-28 Abbvie Biotechnology Ltd Anti-tnf antibody formulations
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
JP5784907B2 (ja) 2007-12-28 2015-09-24 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 組換え型ｖｗｆ製剤
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
EP2113564A1 (de) 2008-05-01 2009-11-04 Arecor Limited Proteinformulierung
CN102066401A (zh) * 2008-05-01 2011-05-18 艾瑞克有限公司 蛋白质制品
EP2328607A1 (de) * 2008-07-16 2011-06-08 Arecor Limited Stabile formulierung eines therapeutischen proteins
EP2341940A1 (de) * 2008-07-16 2011-07-13 Arecor Limited Stabilisierung von proteinen
CA2740919A1 (en) 2008-10-21 2010-04-29 Baxter International Inc. Lyophilized recombinant vwf formulations
CN104398471A (zh) * 2008-11-28 2015-03-11 Abbvie公司 稳定的抗体组合物和用于稳定其的方法
SG175188A1 (en) * 2009-05-04 2011-11-28 Abbott Biotech Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
CA2726230A1 (en) * 2009-07-16 2010-08-19 Arecor Limited The stabilisation of proteins
SI3409289T1 (sl) 2010-02-26 2020-12-31 Novo Nordisk A/S Stabilni sestavki, ki vsebujejo protitelo
LT2542257T (lt) 2010-03-01 2017-11-27 Bayer Healthcare Llc Optimizuoti monokloniniai antikūnai prieš audinių faktoriaus kelio slopiklį (tfpi)
CN102905692B (zh) 2010-05-28 2015-09-16 诺沃—诺迪斯克有限公司 包含抗体和防腐剂的稳定的多剂量组合物
PL2637690T3 (pl) 2010-11-11 2017-03-31 Abbvie Biotechnology Ltd Płynne formulacje zawierające przeciwciało anty-tnf alfa o wysokim stężeniu
GB201113880D0 (en) * 2011-08-12 2011-09-28 Archimed Llp Novel compositions
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
WO2014125237A1 (en) 2013-02-12 2014-08-21 Microarray Limited Novel biosensor
FR3014446B1 (fr) 2013-12-10 2017-05-26 Biomerieux Sa Stabilisation de la gdh en solution aqueuse
CN104480095A (zh) * 2014-11-27 2015-04-01 广西大学 一种酶活力稳定的液态木瓜蛋白酶制剂
GB2556002B (en) 2015-07-07 2020-12-16 Bluewillow Biologics Inc Methods and compositions for nanoemulsion vaccine formulations
US20170007694A1 (en) * 2015-07-07 2017-01-12 Nanobio Corporation Methods and compositions for the stabilization of proteins
KR20180051543A (ko) 2015-09-11 2018-05-16 다우 글로벌 테크놀로지스 엘엘씨 단백질 및 폴리알콕시 지방 화합물을 포함하는 조성물
US10301428B2 (en) 2015-09-11 2019-05-28 Dow Global Technologies Llc Polyalkoxy fatty compound

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3051627A (en) * 1960-08-18 1962-08-28 Armour Pharma Stabilized chymotrypsin solution
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
DE3942141A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh K2p pro-stabilisierung
EP0503583A1 (de) * 1991-03-12 1992-09-16 Takeda Chemical Industries, Ltd. Erythropoietin enthaltendes Arzneimittel mit verzögerter Wirkstofffreigabe
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
IT1247946B (it) 1991-05-17 1995-01-05 Instrumentation Lab Srl Stabilizzazione in forma liquida dell'enzima urato ossidasi
TWI240627B (en) * 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
EA002754B1 (ru) 1996-12-24 2002-08-29 Байоджен, Инк. Устойчивые жидкие составы интерферона
ES2644275T3 (es) * 2000-08-11 2017-11-28 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen anticuerpos
JP2002125693A (ja) * 2000-10-19 2002-05-08 Toyobo Co Ltd 無細胞タンパク質合成用細胞抽出液組成物
EP1409013B1 (de) 2001-07-26 2009-11-18 Novartis Vaccines and Diagnostics S.r.l. Aluminiumadjuvans und histidin enthaltende impstoffe
JP2005502945A (ja) * 2001-08-30 2005-01-27 ボード オブ レジェンツ，ザ ユニバーシティー オブ テキサス システム タンパク質安定性のｐＨ依存性のアンサンブルに基づく分析
US20040234602A1 (en) * 2001-09-21 2004-11-25 Gina Fischer Polymer release system
HUP0402315A3 (en) * 2001-12-21 2009-03-30 Novo Nordisk Healthcare Ag Liquid composition of factor vii polypeptides
GB0202633D0 (en) * 2002-02-05 2002-03-20 Delta Biotechnology Ltd Stabilization of protein preparations
JP5000848B2 (ja) * 2002-05-21 2012-08-15 第一三共株式会社 グレリン含有医薬組成物
BR0317896A (pt) * 2002-12-31 2005-12-06 Altus Pharmaceuticals Inc Complexos de cristais de proteìna e polìmeros iÈnicos
MXPA05013340A (es) * 2003-06-09 2006-03-09 Nastech Pharm Co Composiciones y metodos para liberacion mucosal incrementada de la hormona del crecimiento.
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US20050281879A1 (en) * 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation

Also Published As

Publication number Publication date
WO2007003936A1 (en) 2007-01-11
US20090148406A1 (en) 2009-06-11
JP2008544977A (ja) 2008-12-11
ATE501248T1 (de) 2011-03-15
EP1899462A1 (de) 2008-03-19
DK1899462T3 (da) 2011-06-06
CA2614006C (en) 2014-11-04
CA2614006A1 (en) 2007-01-11
EP2264161A1 (de) 2010-12-22
JP5033798B2 (ja) 2012-09-26
EP2264162A1 (de) 2010-12-22
EP1899462B1 (de) 2011-03-09

Similar Documents

Publication Publication Date Title
ATE501248T1 (de) Stabile wässrige systeme mit proteinen
DE60105362D1 (de) Wässrige kosmetische gele
BRPI0410616A (pt) xampu condicionador
BR0211404A (pt) Aminas, ácidos, aminoácidos e tioéter ácidos substituìdos com perfluoroalquil
BRPI0512396A (pt) polipeptìdeos biossintéticos utilizando aminoácidos codificados não naturalmente
UA87506C2 (ru) Применение электролита как стабилизатора ингибитора
GB2446992A (en) Pathogen-controlling products
CO6612227A2 (es) Formulaciones concentradas acuosas que contienen saflufenacilo y glifosato
RS52706B (en) FORMATION OF DRIED RECONSTITUTED VESICULES FOR PHARMACEUTICAL APPLICATION
DK0977825T3 (da) Flydende enzympræparat og anvendelse heraf
BR0014486A (pt) Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado
TNSN08064A1 (en) Albumin fusion proteins
ATE536369T1 (de) Im wesentlichen ph-wert-unabhängigerweise an serumproteine bindende aminosäuresequenzen, verbindungen, die diese enthalten, und deren verwendung
RS50966B (sr) Agonisti pyy i njihova upotreba
ATE512121T1 (de) Verwendung von cersalzen zur inhibierung der abscheidung von mangan in wassersystemen
BRPI0508227A (pt) géis poliméricos interligados e uso de tais géis poliméricos na recuperação de hidrocarboneto
DE60229958D1 (de) Polymerstabilisierte proteinasen
ATE461276T1 (de) Enzymstabilisierung
ATE365801T1 (de) Modulierung durch il-tif/interleukin-21
BRPI0608020A2 (pt) processo para a produção de uma composição contendo proteìna de soja e composição contendo proteìna de soja
DK1517966T3 (da) Sammensætning på basis af vandig maling, især en lasur eller lak og en kolloid, vandig dispersion af cerium
TR200301248A2 (tr) Antibiyotik Aktiviteye Sahip Olan Farmasotik Kompozisyonlar.
TR200400639T4 (tr) Donmaya-karşı proteinler, bunların üretimleri ve kullanımları
WO2003040181A3 (de) Gene aus corynebacterium glutamicum die für regulatorische proteine codieren
EA200801875A1 (ru) Антагонист cd 80